Showing results (11-20 of 49) with videos related to

Sort By:
Pageof 5
Nature Communications|August 1, 2013
Reductive glutamine metabolism is a function of the α-ketoglutarate to citrate ratio in cellsSarah-Maria Fendt, Eric L Bell, Mark A Keibler, et al.
Molecular Cell|June 3, 2014
Tracing compartmentalized NADPH metabolism in the cytosol and mitochondria of mammalian cellsCaroline A Lewis, Seth J Parker, Brian P Fiske, et al.
Nature Communications|March 2, 2025
Dissecting tumor cell programs through group biology estimation in clinical single-cell transcriptomicsShreya Johri, Kevin Bi, Breanna M Titchen, et al.
Arxiv|September 5, 2025
The Next Layer: Augmenting Foundation Models with Structure-Preserving and Attention-Guided Learning for Local Patches to Global Context Awareness in Computational PathologyMuhammad Waqas, Rukhmini Bandyopadhyay, Eman Showkatian, et al.
Patterns (New York, N.Y.)|August 21, 2023
SwarmDeepSurv: swarm intelligence advances deep survival network for prognostic radiomics signatures in four solid cancersQasem Al-Tashi, Maliazurina B Saad, Ajay Sheshadri, et al.
Arxiv|December 25, 2025
From Classical Machine Learning to Emerging Foundation Models: Review on Multimodal Data Integration for Cancer ResearchAmgad Muneer, Muhammad Waqas, Maliazurina B Saad, et al.
Nature Cancer|February 5, 2022
Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncologyBrendan Reardon, Nathanael D Moore, Nicholas S Moore, et al.
Frontiers in Immunology|December 28, 2023
Distinct patterns of auto-reactive antibodies associated with organ-specific immune-related adverse eventsMehmet Altan, Quan-Zhen Li, Qi Wang, et al.
Journal for Immunotherapy of Cancer|October 6, 2025
Causal AI-based clinical and radiomic analysis for optimizing patient selection in combined immunotherapy and SABR in early-stage NSCLC: a secondary analysis of the phase II I-SABR trialMaliazurina B Saad, Eman Showkatian, Vivek Verma, et al.
Cancers|July 27, 2022
Limited Benefit from the Addition of Immunotherapy to Chemotherapy in TKI-Refractory EGFR-Mutant Lung AdenocarcinomaLingzhi Hong, Whitney E Lewis, Monique Nilsson, et al.
Pageof 5